CA-C3.AI
15.9.2020 15:02:13 CEST | Business Wire | Press release
C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today welcomes data scientists, developers, researchers, and creative thinkers from around the world to participate in the C3.ai™ COVID-19 Grand Challenge . The competition invites participants to leverage data science techniques in new and innovative ways to generate insights that previously were neither apparent nor achievable.
“The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic,” said Thomas M. Siebel, CEO of C3.ai. “As with the C3.ai COVID-19 Data Lake and the C3.ai Digital Transformation Institute , this initiative will tap our community’s collective IQ to make important strides toward necessary, innovative solutions that will help solve a global crisis.”
What Makes a Great Solution
In response to the acute challenges the world faces, the judging panel will prioritize data science projects that help us understand and mitigate the spread of the virus; improve the response capabilities of the medical community; minimize the impact of this disease on society; and help policymakers navigate responses to COVID-19.
Projects may address, but are not limited to:
- Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
- Genome-specific COVID-19 medical protocols, including precision medicine of host responses
- Biomedical informatics methods for drug design and repurposing
- Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
- Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
- Logistics and optimization analysis for design of public health strategies and interventions
- Rigorous approaches to designing sampling and testing strategies
- Data analytics for COVID-19 research harnessing private and sensitive data
- Improving societal resilience in response to the spread of the COVID-19 pandemic
- Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics.
Award Criteria
A panel of judges will evaluate submissions on the extent to which they derive insights, leveraging data science techniques (e.g., statistical analyses, AI/ML algorithms, optimization approaches, etc.) that were not obvious before.
- Pat House, Vice Chairman, C3.ai
- Mike Callagy, County Manager, County of San Mateo
- Richard Levin, Board of Directors, C3.ai and Former President Emeritus, Yale University
- S. Shankar Sastry, Co-Director, C3.ai Digital Transformation Institute and Professor of Electrical Engineering & Computer Sciences, UC Berkeley
- Zico Kolter, Associate Professor of Computer Science, Carnegie Mellon University
The competition is now open with a registration deadline of Oct. 25 and a submission deadline of Nov. 18, 2020. To learn more about how to submit proposals, please visit https://c3.ai/grand-challenge/ .
By Dec. 9, 2020, C3.ai will announce seven competition winners and award $200,000 in cash prizes to the honorees.
- Prizes – There will be one Grand Prize of $100,000, two second-place awards of $25,000 each, and four third-place awards of $12,500 each.
- Publication – The winners will have their work published by C3.ai.
C3.ai COVID-19 Data Lake Expands
The C3.ai™ COVID-19 Data Lake , launched in April 2020, continues to expand and now consists of 40 unique datasets, making it the largest unified, federated image of COVID-19 data in the world. Researchers and developers worldwide can access this free, open-source resource to build models, run analytics, develop tools, and more, without the time and effort of data wrangling.
As part of the C3.ai COVID-19 Grand Challenge, applicants will be required to use the C3.ai COVID-19 Data Lake as a resource to generate new and innovative solutions.
The latest datasets to be integrated into the Data Lake include:
- CDC: Weekly Updates by Select Demographic Characteristics
- COVID Racial Data Tracker from the COVID Tracking Project at The Atlantic
- US Census Bureau: County Population by Age, Sex, Race and Hispanic Origin
- US Bureau of Labor Statistics: County Unemployment Statistics
- Realtor.com: Housing Indicators
- Bureau of Economic Analysis: GDP and Economic Profile by County
- Opportunity Insights: Economic Tracker
- Swayable and TapResearch: COVID-19 Tracker Poll
For additional information about the C3.ai COVID-19 Data Lake, please visit: https://c3.ai/covid
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/grand-challenge/ .
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI® Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
